Estrogen Receptor – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)- Pipeline Review, H2 2019’, provides in depth analysis on Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Women’s Health and Male Health under development targeting Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)

– The report reviews Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Amgen Inc

Arvinas Inc

AstraZeneca Plc

Atossa Genetics Inc

Avivia BV

Eagle Pharmaceuticals Inc

Endece LLC

EndoCeutics Inc

Evestra Inc

H3 Biomedicine Inc

Helixmith Co Ltd

Huons Co Ltd

Jina Pharmaceuticals Inc

Novartis AG

Shenogen Pharma Group Ltd

TTC Oncology LLC

Zenopharm LLC

Zentalis Pharmaceuticals LLC”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) Overview

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) Companies Involved in Therapeutics Development

Arvinas Inc

AstraZeneca Plc

Atossa Genetics Inc

Avivia BV

Eagle Pharmaceuticals Inc

Endece LLC

EndoCeutics Inc

H3 Biomedicine Inc

Huons Global Co Ltd

Novartis AG

Nuevolution AB

Shenogen Pharma Group Ltd

ViroMed Co Ltd

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) Drug Profiles

(bazedoxifene acetate + cholecalciferol) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene + GnRH Agonist + prasterone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene + prasterone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARV-378 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARV-471 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dehydrodiconiferyl alcohol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-372 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Endoxifen Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ERX-11 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosfestrol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-3B5942 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-3B6545 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Libidua Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Loseasonique Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDC-1308 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ESR1 and VEGFR2 for Breast Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ER Alpha for Breast Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ER-Alpha for Breast Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ER-Alpha for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Estrogen Receptor Alpha for Breast Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNG-1153 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNG-8023 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-16234 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTC-352 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZB-716 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) Dormant Products

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) Discontinued Products

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) Product Development Milestones

Featured News & Press Releases

Jul 10, 2018: Cancer Discovery Features H3 Biomedicine Paper Highlighting Effects of Selective Estrogen Receptor Covalent Antagonists (SERCAs) in ERa Wild-Type and Mutant Breast Cancer Models

Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston

Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product

Mar 21, 2018: UIC breast cancer drug in first human clinical trial

Dec 20, 2017: Arvinas Nominates Oral Clinical Candidate for Estrogen Receptor Degrader Program

Dec 11, 2017: AstraZeneca’s Faslodex Rejects For Use Within NHS Scotland

Dec 08, 2017: Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium

Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant

Dec 06, 2017: H3 Biomedicine Presents Preclinical Data on Novel ERa Antagonist at San Antonio Breast Cancer Symposium

Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib

Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib

Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib

Sep 05, 2017: H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer

Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective

Aug 30, 2017: UT Health San Antonio researchers developing drug for recurring ER-positive breast cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Amgen Inc, H2 2019

Pipeline by Arvinas Inc, H2 2019

Pipeline by AstraZeneca Plc, H2 2019

Pipeline by Atossa Genetics Inc, H2 2019

Pipeline by Avivia BV, H2 2019

Pipeline by Eagle Pharmaceuticals Inc, H2 2019

Pipeline by Endece LLC, H2 2019

Pipeline by EndoCeutics Inc, H2 2019

Pipeline by Evestra Inc, H2 2019

Pipeline by H3 Biomedicine Inc, H2 2019

Pipeline by Helixmith Co Ltd, H2 2019

Pipeline by Huons Co Ltd, H2 2019

Pipeline by Jina Pharmaceuticals Inc, H2 2019

Pipeline by Novartis AG, H2 2019

Pipeline by Shenogen Pharma Group Ltd, H2 2019

Pipeline by TTC Oncology LLC, H2 2019

Pipeline by Zenopharm LLC, H2 2019

Pipeline by Zentalis Pharmaceuticals LLC, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports